David James VanderWeele

Grants

Grants per year 2018 2019 2020 2021 2023 2028

• 9 Finished
• 12 Active

Grants per year

Search results

• Finished

  Year 1 award

  Serritella, A. V. (PD/PI) & VanderWeele, D. J. (Other)

  ASCO Cancer Foundation

  7/1/23 → 6/30/24

  Project: Research project

• Prot #BTCRC GU19-404: A Single Arm, Phase I/II Trial of Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men with Localized, High Risk Prostate Cancer

  VanderWeele, D. J. (PD/PI)

  Hoosier Cancer Research Network, Inc., Genentech, Inc

  6/24/21 → 6/24/24

  Project: Research project

• Prot #AFT-47: ARACOG: A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated with Darolutamide or Enzalutamide

  VanderWeele, D. J. (PD/PI)

  Alliance Foundation Trials, LLC, Bayer Consumer Care AG

  4/14/21 → 4/14/25

  Project: Research project

• Prot #7051-ONC-101: A Phase 1 Study of FT-7051 in Men with Metastatic Castration-Resistant Prostate Cancer

  VanderWeele, D. J. (PD/PI)

  Novella Clinical, LLC, FORMA Therapeutics, Inc.

  4/6/21 → 4/6/24

  Project: Research project

• Prot #HPN424-1001: A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy

  VanderWeele, D. J. (PD/PI)

  Harpoon Therapeutics, Inc.

  11/13/20 → 11/13/23

  Project: Research project

• Prot #ARC-6: A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer

  VanderWeele, D. J. (PD/PI)

  Novella Clinical, LLC, Arcus Biosciences, Inc

  11/12/20 → 11/12/24

  Project: Research project

• Prot #B9991040: A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Bempegaldesleukin (NKTR-214) with or without Talazoparib or Enzalutamide in Participants with Locally Advanced or Metastatic Solid Tumors

  VanderWeele, D. J. (PD/PI)

  Pfizer Inc.

  2/10/20 → 2/10/23

  Project: Research project

• Prot #FOR46-001: A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  VanderWeele, D. J. (PD/PI)

  ICON Clinical Research, LLC, Fortis Therapeutics, Inc.

  4/26/19 → 4/26/25

  Project: Research project

• Prot #PCCTC c16-170: Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)

  VanderWeele, D. J. (PD/PI)

  Prostate Cancer Clinical Trials Consortium, LLC

  6/22/18 → 6/22/24

  Project: Research project